Company
Antiva Biosciences
Antiva is developing a novel topical therapeutic for the treatment of oncogenic (high-risk) human papillomavirus (HPV) infections and for the treatment of pre-cancerous cervical lesions caused by HPV in women.
Also known as Antiva Biosciences, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Redwood City, CA, United States
- Legal name
- Antiva Biosciences, Inc.
- antivabio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Antiva Biosciences, Inc. is a clinical stage venture-backed biopharmaceutical company developing a novel, first in class, topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions (CIN 2,3).
Funding snapshot
- Total raised
- $137MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series D+, $53M2023-04-27
Funding rounds
- Series D+
- $53M2023-04-27, Company stated
- Round, 2023
- $38.5M2023-04-24, SEC form D sold, 21 investors
- Series D+
- $31M2021-11-02, Company stated
- Round, 2021
- $15.6M2021-10-25, SEC form D sold, 20 investors
- Round, 2018
- $15M2018-07-06, SEC form D sold, 8 investors
- Series C
- $22M2017-03-28, Company stated
- Round, 2017
- $14.7M2017-02-15, SEC form D sold, 15 investors
- Series B
- $16M2015-08-06, Company stated
- Round, 2015
- $8.9M2015-05-27, SEC form D sold, 26 investors
- Round, 2014
- $1.7M2014-12-08, SEC form D sold, 19 investors
- Round, 2014
- $1.1M2014-06-24, SEC form D sold, 14 investors
- Round, 2013
- $1.1M2013-02-26, SEC form D sold, 18 investors
Products
- Other
- ABI-2280
Loading relationship preview